U.S. Cell & Gene Therapy Bioanalytical Testing Services Market Size & Outlook

The cell & gene therapy bioanalytical testing services market in the United States is expected to reach a projected revenue of US$ 314.4 million by 2030. A compound annual growth rate of 7.5% is expected of the United States cell & gene therapy bioanalytical testing services market from 2024 to 2030.
Revenue, 2023 (US$M)
$189.0
Forecast, 2030 (US$M)
$314.4
CAGR, 2024 - 2030
7.5%
Report Coverage
U.S.

U.S. cell & gene therapy bioanalytical testing services market, 2018-2030 (US$M)

U.S.

Related Markets

U.S. cell & gene therapy bioanalytical testing services market highlights

  • The U.S. cell & gene therapy bioanalytical testing services market generated a revenue of USD 189.0 million in 2023 and is expected to reach USD 314.4 million by 2030.
  • The U.S. market is expected to grow at a CAGR of 7.5% from 2024 to 2030.
  • In terms of segment, bioavailability & bioequivalence studies was the largest revenue generating test type in 2023.
  • Bioavailability & Bioequivalence Studies is the most lucrative test type segment registering the fastest growth during the forecast period.


Cell & gene therapy bioanalytical testing services market data book summary

Market revenue in 2023USD 189.0 million
Market revenue in 2030USD 314.4 million
Growth rate7.5% (CAGR from 2023 to 2030)
Largest segmentBioavailability & bioequivalence studies
Fastest growing segmentBioavailability & Bioequivalence Studies
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationBioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type
Key market players worldwideIQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC


Other key industry trends

  • In terms of revenue, U.S. accounted for 37.3% of the global cell & gene therapy bioanalytical testing services market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In North America, U.S. cell & gene therapy bioanalytical testing services market is projected to lead the regional market in terms of revenue in 2030.
  • U.S. is the fastest growing regional market in North America and is projected to reach USD 314.4 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cell & Gene Therapy Bioanalytical Testing Services Market Scope

Cell & gene therapy bioanalytical testing services market segmentation & scope
Bioavailability & Bioequivalence Studies
Pharmacokinetics
Pharmacodynamics
Other test type
Ex-vivo
In-vivo
CAR T-cell therapies
CAR-NK cell therapy
TCR-T cell therapy
Other
Cell Therapy
Gene Therapy
Gene-Modified Cell Therapy
Cell Therapy
Gene Therapy
Gene-Modified Cell Therapy
Cell Therapy
Oncology
Infectious Diseases
Neurological disorders
Rare Diseases
Others

Cell & Gene Therapy Bioanalytical Testing Services Market Companies

Name Profile # Employees HQ Website

U.S. cell & gene therapy bioanalytical testing services market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.


Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.4% in 2023. Horizon Databook has segmented the U.S. cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.


The U.S. accounts for the highest share of the global cell & gene therapy bioanalytical testing services market, as many pharmaceutical and biotechnology companies operate in this country. Increasing R&D investments and growing partnerships & collaborations among academic institutions, biopharmaceutical corporations, & CROs are contributing to the growth of cell and gene therapy bioanalytical testing services.

These partnerships promote innovation and market growth by facilitating information sharing, resource access, and common infrastructure for bioanalytical testing.

Reasons to subscribe to U.S. cell & gene therapy bioanalytical testing services market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of U.S. cell & gene therapy bioanalytical testing services market databook

  • Our clientele includes a mix of cell & gene therapy bioanalytical testing services market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the U.S. cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into U.S. cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

U.S. cell & gene therapy bioanalytical testing services market size, by test type, 2018-2030 (US$M)

U.S. Cell & Gene Therapy Bioanalytical Testing Services Market Outlook Share, 2023 & 2030 (US$M)

U.S. cell & gene therapy bioanalytical testing services market size, by test type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more